Clinical Trials
Persistence Pays Off - Validating STEAP1 as a Target for Prostate Cancer Therapeutic Delivery
Six Transmembrane Epithelial Antigen of the Prostate (STEAP1) is a member of a family of metalloreductases that have ability to form heterodimers or heterotrimers with other STEAP family proteins.1 The function of STEAP1 is quite broad. It has known functional roles in cell proliferation, invasion, and epithelial to mesenchymal transition (EMT).2-4 STEAP1 is an antigen highly expressed in most prostate cancers, with limited normal tissue expression.2 STEAP1 is especially highly expressed in metastatic castration-resistant prostate cancer in both metastatic lesions to the bone and also in lymph nodes.5 For this reason, it has been considered a highly promising therapeutic target for novel drug delivery systems for men who harbor metastatic castration-resistant prostate cancer.
Evan Y. Yu, MD
Evan Yu, a medical oncologist, treats prostate, bladder, and testicular cancer and is passionate about providing a personalized medical approach to a selection of novel therapies as well as understanding biological mechanisms of drug sensitivity and resistance.
Clinical Expertise
Medical Oncology, Translational Research, Novel molecular targeted agents, Biomarkers, Imaging (PET scans, MRI), Bone health.
- Section Head, Cancer Medicine, Clinical Research Division Fred Hutchinson Cancer Center
- Medical Director, Clinical Research Support Fred Hutchinson Cancer Research Consortium
- Professor of Medicine Division of Oncology, Department of Medicine University of Washington School of Medicine Seattle, WA
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care. Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.